Fidelity Investments
RLMD icon

Fidelity Investments’s Relmada Therapeutics RLMD Stock Holding History

Fidelity Investments’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,062
Closed -$15.6K – 5635
2024
Q4 		$15.6K Sell
30,062
-86,482
-74% -$211K ﹤0.01% 4282
2024
Q3 		$378K Buy
116,544
+26,185
+29% +$84.8K ﹤0.01% 2972
2024
Q2 		$271K Buy
90,359
+6,512
+8% +$23.6K ﹤0.01% 2935
2024
Q1 		$390K Sell
83,847
-301
-0.4% -$1.45K ﹤0.01% 2807
2023
Q4 		$348K Sell
84,148
-132
-0.2% -$391 ﹤0.01% 2783
2023
Q3 		$253K Sell
84,280
-269
-0.3% -$799 ﹤0.01% 2814
2023
Q2 		$208K Sell
84,549
-4,929
-6% -$13.6K ﹤0.01% 2940
2023
Q1 		$202K Buy
89,478
+5,723
+7% +$19.7K ﹤0.01% 2974
2022
Q4 		$292K Buy
83,755
+83,151
+13,767% +$730K ﹤0.01% 2893
2022
Q3 		$22K Buy
604
+386
+177% +$10.7K ﹤0.01% 3811
2022
Q2 		$4K Sell
218
-15
-6% -$327 ﹤0.01% 4399
2022
Q1 		$6K Buy
233
+213
+1,065% +$4.4K ﹤0.01% 4396
2021
Q4 		$0 Buy
+20
New +$445 ﹤0.01% 4844

Other funds holding RLMD

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

Fidelity Investments's RLMD Position: Q1 2025 in Review

Fidelity Investments sold out of Relmada Therapeutics (RLMD) in Q1 2025, closing a stake of 30,062 shares — an estimated $15.6K sold.

Fidelity Investments first reported a position in RLMD in Q4 2021 and held it in 13 quarters. The position peaked at $390K in Q1 2024. 44 funds tracked by Wall St. Rank hold RLMD as of Q1 2025.

  • Fidelity Investments reported no remaining Relmada Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Fidelity Investments sold 30,062 Relmada Therapeutics shares in Q1 2025, an estimated $15.6K.
  • Fidelity Investments first reported a position in Relmada Therapeutics in Q4 2021 and held it in 13 quarters.
  • Fidelity Investments's Relmada Therapeutics position peaked at $390K in Q1 2024.
  • 44 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2025.

Based on Fidelity Investments's 13F filing for Q1 2025, filed 12 May 2025.